TXG - 10X Genomics - Stock Price & Dividends

10x Genomics Inc. is a life science technology company that develops and commercializes innovative instruments, consumables, and software for analyzing complex biological systems.

The company's product portfolio includes the Chromium, Chromium Connect, and Chromium Controller instruments, as well as microfluidic chips, slides, reagents, and other consumables. These products are designed to work in tandem with its single cell solutions, which enable researchers to gain a deeper understanding of biological systems at the individual cell level.

10x Genomics' single cell solutions offer a range of applications, including single cell gene expression, which measures gene activity and networks on a cell-by-cell basis; single cell immune profiling, which studies the immune system; single cell Assay for Transposase Accessible Chromatin (ATAC) solution, which helps understand the epigenetic state; and single cell multiome ATAC + gene expression, which enables simultaneous analysis of both RNA and chromatin accessibility in a single cell.

In addition to its single cell solutions, the company also provides the Visium platform, which allows researchers to understand the spatial positions of biological analytes within tissues at high resolution, and the Xenium platform, which enables in situ analysis.

10x Genomics serves a diverse range of customers, including academic institutions, government agencies, biopharmaceutical companies, biotechnology firms, and other organizations. The company was founded in 2012 and is headquartered in Pleasanton, California, with a strong online presence at https://www.10xgenomics.com.

With a global reach that spans the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific, 10x Genomics is well-positioned to drive innovation and advancements in the life sciences industry.